FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:1604-1611 November 27, 1997 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Multiple sclerosis is a common disease of the central nervous system affecting approximately 1 million young adults, mostly women, worldwide.¹ It is characterized by episodic neurologic symptoms that are often followed by fixed neurologic deficits, increasing disability, and medical, socioeconomic, and physical decline over a period of 30 to 40 years.

For most of the 20th century, multiple sclerosis was considered untreatable. In 1982, the Multiple Sclerosis Society of Canada and the National Multiple Sclerosis Society of the United States sponsored the first international workshop on therapeutic trials.² This workshop served to usher in an era of activism and optimism . . . [Full Text of this Article]

Disease Characteristics Related to Treatment Decisions

Design of Clinical Trials

Relation between Treatment Strategies and Pathogenesis

Controlled Clinical Trials

Relapsing Multiple Sclerosis

Corticosteroids

Interferon Beta

Glatiramer Acetate

Azathioprine

Intravenous Immune Globulin

Progressive Multiple Sclerosis

Methotrexate

Cyclophosphamide

Cyclosporine

Future Directions

Source Information

From the Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, Cleveland, OH 44106, where reprint requests should be addressed to Dr. Rudick.

References

This article has been cited by other articles:

• Dutta, R., Trapp, B. D. (2007). Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 68: S22-S31 [Abstract] [Full Text]  
• Choudry, B. A., Chan, J. W. (2007). An Update on Monoclonal Antibody Therapies in Multiple Sclerosis. Journal of Pharmacy Practice 20: 167-180 [Abstract]  
• Confavreux, C., Vukusic, S. (2006). Age at disability milestones in multiple sclerosis. Brain 129: 595-605 [Abstract] [Full Text]  
• Schwarting, A., Paul, K., Tschirner, S., Menke, J., Hansen, T., Brenner, W., Kelley, V. R., Relle, M., Galle, P. R. (2005). Interferon-{beta}: A Therapeutic for Autoimmune Lupus in MRL-Faslpr Mice. J. Am. Soc. Nephrol. 16: 3264-3272 [Abstract] [Full Text]  
• Natarajan, N., Weinstein, R. (2005). Therapeutic Apheresis in Neurology Critical Care. J Intensive Care Med 20: 212-225 [Abstract]  
• Perlas, A., Chan, V. W. S. (2005). Neuraxial anesthesia and multiple sclerosis/Anesthesie neuraxiale et sclerose en plaques. Canadian J. Anesthesia 52: 454-458 [Full Text]  
• Buchanan, R. J, Martin, R. A, Zuniga, M., Wang, S., Kim, M. (2004). Nursing home residents with multiple sclerosis: comparisons of African American residents to white residents at admission. Mult Scler 10: 660-667 [Abstract]  
• Siev-Ner, I, Gamus, D, Lerner-Geva, L, Achiron, A (2003). Refiexology treatment relieves symptoms of multiple sclerosis: a randomized controlled study. Mult Scler 9: 356-361 [Abstract]  
• Berger, T., Rubner, P., Schautzer, F., Egg, R., Ulmer, H., Mayringer, I., Dilitz, E., Deisenhammer, F., Reindl, M. (2003). Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating Event. NEJM 349: 139-145 [Abstract] [Full Text]  
• Confavreux, C., Vukusic, S., Adeleine, P. (2003). Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126: 770-782 [Abstract] [Full Text]  
• Buchanan, R J, Wang, S, Ju, H (2002). Analyses of the minimum data set: comparisons of nursing home residents with multiple sclerosis to other nursing home residents. Mult Scler 8: 512-522 [Abstract]  
• Buchanan, R. J, Wang, S., Huang, C., Graber, D. (2001). Profiles of nursing home residents with multiple sclerosis using the minimum data set. Mult Scler 7: 189-200 [Abstract]  
• Huang, D., Wang, J., Kivisakk, P., Rollins, B. J., Ransohoff, R. M. (2001). Absence of Monocyte Chemoattractant Protein 1 in Mice Leads to Decreased Local Macrophage Recruitment and Antigen-specific T Helper Cell Type 1 Immune Response in Experimental Autoimmune Encephalomyelitis. J. Exp. Med. 193: 713-726 [Abstract] [Full Text]  
• Confavreux, C., Vukusic, S., Moreau, T., Adeleine, P. (2000). Relapses and Progression of Disability in Multiple Sclerosis. NEJM 343: 1430-1438 [Abstract] [Full Text]  
• Wolinsky, J. S., Narayana, P. A., Noseworthy, J. H., Lublin, F. D., Whitaker, J. N., Linde, A., Gjorstrup, P., Sullivan, H. C. (2000). Linomide in relapsing and secondary progressive MS: Part II: MRI results. Neurology 54: 1734-1741 [Abstract] [Full Text]  
• Scanderbeg, A. C., Tomaiuolo, F., Sabatini, U., Nocentini, U., Grasso, M. G., Caltagirone, C. (2000). Demyelinating Plaques in Relapsing-remitting and Secondary-progressive Multiple Sclerosis: Assessment with Diffusion MR Imaging. Am. J. Neuroradiol. 21: 862-868 [Abstract] [Full Text]  
• Karussis, D., Weiner, H. L, Abramsky, O. (1999). Multiple sclerosis vs Lyme disease: A case presentation to a discussant and a review of the literature. Mult Scler 5: 395-402  
• Rudick, R. A. (1999). Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics. Arch Neurol 56: 1079-1084 [Full Text]  
• Kwon, O. J., Karni, A., Israel, S., Brautbar, C., Amar, A., Meiner, Z., Abramsky, O., Karussis, D. (1999). HLA Class II Susceptibility to Multiple Sclerosis Among Ashkenazi and Non-Ashkenazi Jews. Arch Neurol 56: 555-560 [Abstract] [Full Text]  
• Smith, P. F, Darlington, C. L (1999). Recent developments in drug therapy for multiple sclerosis. Mult Scler 5: 110-120 [Abstract]  
• Rudick, R. A. (1998). A 29-Year-Old Man With Multiple Sclerosis. JAMA 280: 1432-1439 [Full Text]